NCT00963547 2024-06-04
MK-2206-015
Merck Sharp & Dohme LLC
Phase 1 Terminated
Clinical Trials
12 trialsNCT01199367 2024-04-25
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Terminated
NCT00251433 2023-03-31
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
Novartis
Phase 1 Terminated
NCT00447122 2022-03-08
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Brown University
Phase 1 Terminated
NCT00634088 2016-03-10
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
R-Pharm
Phase 1 Terminated
NCT01497626 2016-02-17
Lapatinib and Bortezomib in Patients With Advanced Malignancies
Georgetown University
Phase 1 Terminated
NCT02131506 2016-02-02
CAELYX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1 Terminated
NCT01281163 2015-08-27
Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01238029 2014-11-21
CELAVIE
Sponsor GmbH
Phase 1 Terminated
NCT01705340 2013-09-30
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00804310 2012-03-28
UCDCC#207
University of California, Davis
Phase 1 Terminated
NCT00317434 2009-12-15
Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
University of Alabama at Birmingham
Phase 1 Terminated